Due to their favorable outcomes in terms of glycemic control and weight loss properties, GLP-1 RAs are becoming more commercially available
From the doseinhibition curves obtained in vitro we can estimate that this equates to a GLP-1(936) concentration of 30 pmol/l, in remarkably good agreement with the plasma GLP-1 concentration observed in vivo
202,203,204,205,206,207,208,209 Utilizing data from observational epidemiologic studies in conjunction with experimental evidence from in vitro and animal model investigations, elevated serum urate levels have been suggested as being potentially linked to concurrent metabolic disorders
Our clinical decisions are guided by: The strength and quality of available evidence Individual medical and psychiatric history Safety, side-effect profiles, and long-term risk How any new approach integrates with comprehensive, whole-person care If GLP-1 medications eventually prove safe and effective for certain patients with substance use disorders, they would be considered as part of a broader, medically directed treatment plannever as a standalone quick fix. In the meantime, my advice to patients is straightforward: have this conversation with your treatment team
longer studies in disease models (for example, kidney aging) suggest benefits at defined doses, but comprehensive long-term safety pharmacology remains sparse in the public domain
